Focus: Characterize and Develop Next Generation Therapeutics for Lethal Prostate and Breast Cancers
One of a major goals of my research laboratory is to characterize epigenetic regulators promoting survival, adaptability and metastasis of lethal cancers, particularly hormone refractory prostate cancers and characterize novel small molecule inhibitors that we have identified as having potent anti-tumor activity against metastatic prostate cancers. We are interested in dissecting epigenetic regulators driving castration resistance and drug resistance. Our lab is focused on WD40 repeat containing proteins, bromodomain proteins and ubiquitin ligases as epigenetic regulators of disease specific targets. The overall idea is to develop a robust pharmacogenomics pipeline to advance novel inhibitors as cancer therapeutics.
A second interest of our lab which cuts into the existing interest in prostate cancer, is the epigenetic regulation of DNA damage signaling pathways. Based on the notion that genome instability drives tumor heterogeneity, clonal adaptation and drug resistance, and intact DNA repair pathways are critical to maintain the integrity of the genomes, we are characterizing novel regulators of genome stability and how these may be compromised as prostate cancer progresses to castration resistant stage. We are characterizing non-coding RNAs regulating the tumor suppressor gene p53 and how they epigentically regulate the DNA damage signaling pathways.
Kiran Mahajan Ph.D
Primary Appointment: Assistant Member, Tumor Biology Department
Secondary Appointment: Assistant Member, Genitourinary Oncology Department
Moffitt Comprehensive Cancer Center
Assistant Professor, Department of Oncological Sciences
Courtesy Appointment: Cell Biology, Microbiology and Molecular Biology Department
Cancer Biology Program
University of South Florida, Tampa, Florida
Tel: 813 745 4062
For Postdoctoral fellowship enquires please contact